EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte Studie

Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial

Livia Marrazzo, Icro Meattini, Carlotta Becherini, Viola Salvestrini, Luca Visani, Giuseppe Barletta, Calogero Saieva, Maria Riccarda Del Bene, Giuseppe Pilato, Isacco Desideri, Chiara Arilli, Lisa Paoletti und 9 weitere

La radiologia medica · 2024

DOI: 10.1007/s11547-024-01897-6 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift La radiologia medica, 2024. Verfasst von Livia Marrazzo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. Hauptthemen laut MEDLINE: Anthracyclines, Ramipril, Bisoprolol. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: This study, derived from the phase 3 SAFE trial (ClinicalTrials.gov identifier: NCT2236806), explores subclinical cardiac damage in breast cancer patients receiving anthracycline-based chemotherapy and left-sided breast radiation therapy (RT). MATERIALS AND METHODS: Eligible patients were randomized to a cardioprotective pharmacological therapy (bisoprolol, ramipril, or both) or placebo, with cardiac surveillance at multiple time-point using standard and 3-dimensional echocardiography. Dosimetric parameters were analysed, including mean heart dose (MHD) and various metrics for heart substructures, employing advanced contouring techniques and auto-contouring software. RESULTS: In the analysis of left-sided breast RT patients, the study encompassed 39 out of 46 irradiated individuals, focusing on GLS and 3D-LVEF outcomes with ≥ 10% worsening, defined as subclinical heart damage. Distinct RT schedules were used, with placebo exhibiting the highest ≥ 10% worsening (36.4%). In terms of treatment arms, bisoprolol exhibited 11.1% worsening, while ramipril 16.7% and bisoprolol + ramipril 25%. For patients with no subclinical damage, the mean MHD was 1.5 Gy; for patients with subclinical heart damage, the mean MHD was 1.6 Gy (p = 0.94). Dosimetric parameters related to heart and heart substructures (left anterior descending artery, right and left atrium, right and left ventricle) showed no statistically significant differences between patients with and without subclinical damage. CONCLUSION: Our results emphasize the crucial role of cardioprotective measures in mitigating adverse effects, highlighting RT as having negligible influence on cardiac performance. An extended follow-up assessment of the whole series is warranted to determine whether a subclinical effect could significantly influence clinical outcomes and cardiac events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthracyclinesRamiprilBisoprololHumansFemaleMiddle AgedBreast NeoplasmsAdultAgedCardiotoxicityEchocardiography, Three-DimensionalHeartUnilateral Breast NeoplasmsCardiotonic Agents

Stichwörter der Autor:innen

Anthracycline-based chemotherapyBreast cancerCardioprotective therapyLeft-sided breast radiotherapySubclinical cardiac damage

Substanzen

AnthracyclinesRamiprilBisoprololCardiotonic Agents

Autor:innen und Institutionen

  • Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy.
  • Medical Physics Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • Department of Experimental and Clinical Biomedical Sciences "M. Serio", University of Florence, Florence, Italy. icro.meattini@unifi.it.
  • Radiation Oncology and Breast Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 50, 50134, Florence, Italy. icro.meattini@unifi.it.
  • Radiation Oncology and Breast Unit, Oncology Department, Azienda Ospedaliero-Universitaria Careggi, Viale Morgagni 50, 50134, Florence, Italy.
  • CardioThoracic and Vascular Department, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.

Zitieren

APA

Marrazzo, L., Meattini, I., Becherini, C., Salvestrini, V., Visani, L., Barletta, G., Saieva, C., Del Bene, M. R., Pilato, G., Desideri, I., Arilli, C., Paoletti, L., Russo, S., Scoccianti, S., Martella, F., Francolini, G., Simontacchi, G., Nori Cucchiari, J., Pellegrini, R., …, & Pallotta, S. (2024). Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial. La radiologia medica. https://doi.org/10.1007/s11547-024-01897-6

Vancouver

Marrazzo L, Meattini I, Becherini C, Salvestrini V, Visani L, Barletta G, et al. Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial. La radiologia medica. 2024. doi:10.1007/s11547-024-01897-6

BibTeX
@article{Marrazzo2024,
  author = {Marrazzo, Livia and Meattini, Icro and Becherini, Carlotta and Salvestrini, Viola and Visani, Luca and Barletta, Giuseppe and Saieva, Calogero and Del Bene, Maria Riccarda and Pilato, Giuseppe and Desideri, Isacco and Arilli, Chiara and Paoletti, Lisa and Russo, Serenella and Scoccianti, Silvia and Martella, Francesca and Francolini, Giulio and Simontacchi, Gabriele and Nori Cucchiari, Jacopo and Pellegrini, Roberto and Livi, Lorenzo and Pallotta, Stefania},
  title = {Subclinical cardiac damage monitoring in breast cancer patients treated with an anthracycline-based chemotherapy receiving left-sided breast radiation therapy: subgroup analysis from a phase 3 trial},
  journal = {La radiologia medica},
  year = {2024},
  doi = {10.1007/s11547-024-01897-6}
}
Kostenlos starten →